{
    "clinical_study": {
        "@rank": "105992", 
        "acronym": "HCC DC CTL", 
        "arm_group": [
            {
                "arm_group_label": "The foundation treatment  after radical operation or RFA", 
                "arm_group_type": "Other", 
                "description": "The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment"
            }, 
            {
                "arm_group_label": "MASCT:Multiple Antigens Specific Cellular Therapy", 
                "arm_group_type": "Experimental", 
                "description": "autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total  17 antigens"
            }
        ], 
        "brief_summary": {
            "textblock": "To prove that the efficacy and safety of 'MASCT group' is superior to 'non-treatment group'\n      in patient undergone curative resection (RFA or operation) for hepatocellular carcinoma in\n      China."
        }, 
        "brief_title": "Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient is diagnosed as hepatocellular carcinoma(HCC) by pathological/\n             radiological test\n\n          -  No matter how the patient has been treated before, his (her) tumor should be totally\n             removed by curative resection (PEIT, RFA or operation) in 8 weeks.at least 4 weeks\n             later ,The tumor's removal should be perfectly confirmed by radiological test; on\n             dynamic CT, dynamic MRI or on angiography\n\n          -  Child-Pugh Score should be less than 9\n\n          -  ECOG Performance status (ECOG-PS) is less than 2 or equal to\n\n          -  Patient's remaining life-time should be expected at least more than 2 years\n\n          -  Patient should meet below conditions by blood test, kidney and liver function test\n             Re-evaluation is possible during screening\uff1a\n\n          -  Leukocyte count is more than 3 * 109/L)\n\n          -  Absolute Neutrophil Count (ANC) is more than or equal to 1,000/\u00b5L\n\n          -  Hemoglobin is more than or equal to 85 g/L\n\n          -  Thrombocyte count is more than (5 *1010/L)\n\n          -  Prothrombin Time(PT) normal or Overtime is not more than 3 seconds\n\n          -  Blood urea nitrogen(BUN) and serum Creatinine is less than or equal to 1.5 multiply\n             normal upper-limit\n\n          -  patient is fully explained about the purpose/ contents and characteristics of the\n             testing medication, and the patient him(her)self,the guardian or the legal\n             representative signed on written consent\n\n        Exclusion Criteria:\n\n          -  Hepatocellular carcinoma has been transferred or liver residual tumor by\n             pathological/ radiological test\n\n          -  The carcinoma has been invaded to main portal vein or major branch hepatic vein\n\n          -  Patient who has disease history of immune deficiency (which can be worse by\n             immunotherapy) or auto-immune disease (ex. arthritis rheumatism, Burger's\n             disease,multiple sclerosis and adolescent-occurred insulin dependent diabetes)\n\n          -  Patient who has disease history of malignant tumor within 5 years before this\n             clinical trial. (except for skin cancer, local prostate cancer or carcinoma in situ\n             of the uterine cervix\n\n          -  Patient who has serious disease in other organs after tumor resection.\n\n          -  Patient has serious mental disease by sub- investigator's opinion\n\n          -  Patient who is incongruent to this clinical trial by sub- investigator's opinion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02026362", 
            "org_study_id": "SYZ Cell Therapy Co.."
        }, 
        "intervention": [
            {
                "arm_group_label": "MASCT:Multiple Antigens Specific Cellular Therapy", 
                "description": "autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .", 
                "intervention_name": "MASCT:Multiple Antigens Specific Cellular Therapy", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "The foundation treatment  after radical operation or RFA", 
                    "MASCT:Multiple Antigens Specific Cellular Therapy"
                ], 
                "intervention_name": "The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "HCC", 
            "DC", 
            "CTL"
        ], 
        "lastchanged_date": "February 16, 2014", 
        "link": [
            {
                "url": "http://www.thyx.com/"
            }, 
            {
                "url": "http://www.nfyy.com/"
            }, 
            {
                "url": "http://www.sysucc.org.cn/"
            }, 
            {
                "url": "http://www.zssy.com.cn/"
            }
        ], 
        "location": {
            "contact": {
                "email": "chenping@thyx.com", 
                "last_name": "PEGGY CHEN, Master", 
                "phone": "00860755-86964231"
            }, 
            "facility": {
                "address": {
                    "city": "Shenzhen", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "518006"
                }, 
                "name": "JOE ZHOU"
            }, 
            "investigator": [
                {
                    "last_name": "GUO YA JUN, PHD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "XIA JIAN CHUAN, PHD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "ZHANG QI, PHD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Open-label, Multi-center Clinical Trial to Compare the Efficacy and Safety of MASCT Group' and 'Non-treatment Group' in Patient Undergone Curative Resection( RFA or Operation) for Hepatocellular Carcinoma .MASCT That Expresses Multiple Antigens Specific Cellular Therapy,Autologous Immune Cytotoxic of T-lymphocytes(CTL) Induced by Dendritic Cell(DC) Loaded With Multiple Antigens", 
        "other_outcome": [
            {
                "measure": "T cell subsets figures", 
                "safety_issue": "No", 
                "time_frame": "an expected average of 16weeks"
            }, 
            {
                "measure": "cytokine secretion figures", 
                "safety_issue": "No", 
                "time_frame": "an expected average of 16weeks"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants with tumor recurrence metastasis as a Measure of effectiveness", 
                "safety_issue": "No", 
                "time_frame": "2years"
            }, 
            {
                "measure": "The time duration of Participants from operation to tumour recurrence or metastasis as a Measure of  effectiveness", 
                "safety_issue": "No", 
                "time_frame": "2years"
            }, 
            {
                "description": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "2years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02026362"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Hepatitis B virus markers figures", 
                "safety_issue": "No", 
                "time_frame": "an expected average of 18 weeks"
            }, 
            {
                "measure": "Serum hepatitis B virus (HBV)DNA figures", 
                "safety_issue": "No", 
                "time_frame": "an expected average of 16 weeks"
            }
        ], 
        "source": "SYZ Cell Therapy Co..", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Nanfang Hospital of Southern Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Third Affiliated Hospital, Sun Yat-Sen University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Sun Yat-sen University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "SYZ Cell Therapy Co..", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}